• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Q3 Earnings Report Change GRAIL's (GRAL) Narrative

    Simply Wall St·11/14/2026 15:20:27
    Listen to the news
    • GRAIL reported Q3 2026 revenue of US$37.54 million and a net loss of US$103.57 million, with basic loss per share from continuing operations of US$2.21.
    • Across the first nine months of 2026, GRAIL generated US$123.01 million in revenue while holding its cumulative net loss broadly steady at US$307 million compared with the prior year period.
    • We will now look at how GRAIL’s higher year to date revenue, but still heavy losses, could reshape the broader investment narrative.

    Scan beyond GRAIL and line up other loss making stories with meaningful top line traction through our curated list of 20 high quality undiscovered gems to see how this profile compares.

    GRAIL Investment Narrative Recap

    To own GRAIL, you need to believe its multi cancer early detection platform can grow into a much larger screening and diagnostics franchise while eventually bringing losses under tighter control. The analyst consensus Narrative on Simply Wall St anchors on that idea. Q3 reinforces both sides of the story, with year to date revenue progress but a quarterly net loss of US$103.57 million still front and center.

    The main near term catalyst is execution around Galleri, including FDA review, payer discussions and cost per test. The latest figures show revenue at US$37.54 million for Q3 and US$123.01 million for the nine month period, while cumulative losses stay heavy. That keeps the biggest risk in plain sight: sustained cash burn and pricing pressure.

    The most relevant recent update is GRAIL’s Q3 and nine month 2026 report. Sales and revenue for both periods are set out clearly, alongside continuing large losses and loss per share metrics. For anyone watching catalysts around scale up and unit economics, those numbers give a fresh checkpoint on how the commercial model is holding up.

    Higher year to date revenue, combined with a broadly steady nine month net loss relative to the prior year period, feeds into the existing catalysts around Medicare focused legislation, payer uptake and cost of goods reduction. It also underlines the risk flagged in the analyst consensus Narrative on Simply Wall St that earnings and cash flow may stay under pressure, especially if pricing and royalty headwinds persist.

    GRAIL's narrative projects revenue of US$378.7 million and earnings of US$75.1 million by 2029. This profile is built on analyst assumptions of 31.5% yearly revenue growth and an earnings swing of about US$481.3 million from current earnings of a US$406.2 million loss.

    Uncover why GRAIL's fair value indicates a 14% potential upside to its current price, which could narrow quickly.

    NasdaqGS:GRAL 1-Year Stock Price Chart
    NasdaqGS:GRAL 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bullish twist on GRAIL focuses on international expansion rather than just FDA and Medicare timelines. The most optimistic analysts were sketching out revenue of about US$418.4 million and earnings of roughly US$76.5 million by 2029, before this Q3 update. You can compare those upbeat expectations with your own view and decide whether this new earnings report nudges that story higher or lower.

    Explore 3 other GRAIL fair value estimates, including one that suggests potential upside of up to 55% from the current price.

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that is truly your own.

    Looking for more investment ideas beyond GRAIL?

    If GRAIL has sharpened your thinking on risk, reward and time horizon, use that same framework to compare other opportunities side by side in the Simply Wall St Screener.